ArticlePLOS global public health2026
Isoniazid monotherapy for tuberculosis prevention during pregnancy and adverse outcomes in women living with HIV in Uganda: A propensity score-weighted analysis of routine care data.
Article in PLOS global public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Data on the safety of tuberculosis preventive treatment (TPT) during pregnancy particularly from routine care settings in high tuberculosis (TB) burden countries remain limited. We evaluated the association between TPT exposure during pregnancy and adverse pregnancy outcomes among pregnant women living with HIV (WLHIV) in Uganda. We conducted a retrospective cohort study using routinely collected data from five public urban primary health facilities in Kampala, Uganda. We included pregnant women living with HIV on antiretroviral therapy (ART) between 2016 and 2022. The primary outcome was a composite of adverse pregnancy outcomes: miscarriage, stillbirth, low birth weight, neonatal complications, or maternal/neonatal death. A secondary composite outcome excluded neonatal and maternal death. There was no preterm delivery documented in this sample. The primary exposure was 6-month isoniazid preventive therapy (IPT) during pregnancy. We applied inverse probability of treatment weighting (IPTW) using propensity scores from logistic regression to adjust for confounding. Missing data on covariates and outcome were addressed using multiple imputation. Analysis was performed using R software v.4.3.3. We analyzed data from 521 pregnant WLHIV, the median age was 28 years (interquartile range 24-31), 44% of whom received IPT during pregnancy. Overall, 10.0% experienced an adverse pregnancy outcome. No significant differences were observed between IPT-exposed and unexposed groups for the primary (10.3% vs. 9.6%; p = 0.81) or secondary (10.3% vs. 8.5%; p = 0.50) composite outcomes. IPTW-adjusted analysis showed no significant association between IPT exposure and adverse pregnancy outcomes (weighted OR: 1.06; 95% CI: 0.68-1.63; p = 0.81). Sensitivity and subgroup analyses yielded consistent findings. Exposure to 6-month isoniazid TPT during pregnancy was not statistically associated with adverse pregnancy outcomes among women on ART in routine care settings. Strengthened pharmacovigilance and systematic clinical reporting are essential to ensure maternal and neonatal safety as TPT coverage expands in high TB/HIV burden settings.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.